Mitoquinone (MitoQ) and endurance

What 2 graded rows on mitoquinone (mitoq) agree on for endurance, and where they differ. Counted side by side, never averaged.

Consensus finder Rows from the Mitoquinone (MitoQ) page, reviewed Oct 21, 2026 How it decides

What the rows agree on

Each block and row is one graded row from the Mitoquinone (MitoQ) page, with its PubMed record.

Supplement

Mitoquinone (MitoQ) Choose another

2 rows · 207 people

Split. 1 row found an improvement and 1 found no difference.

No difference

Improved

Each block is one evidence row, sized by how many people it enrolled, with its grade inside.

From the rows

Trial sizeStudy designWho was studiedWhen publishedGrade

The best-graded row, grade C, is a meta-analysis of 188 people (2024) and found no difference.

The row that found no difference was larger: 188 people, against 19 people for the row that found an improvement.

The row that found no difference is a pooled review of several trials; the row that found an improvement is a single study.

Only the row that found an improvement names men and athletes or trained people in its population.

The row that found no difference is newer (2024) than the row that found an improvement (2021).

The best grade is C among the row that found no difference, and D among the row that found an improvement.

1 improved · 1 no difference

Grade D8 km cycling time-trial performance · Improved
Crossover RCT · n 19 · 2021 · Middle-aged, recreationally trained male cyclists (mean age 44)
20 mg per day · 28 days
Time-trial completion was 1.3% faster with MitoQ than placebo (12.91 vs 13.09 minutes; small effect, d = 0.2) with no difference in perceived exertion.
Row on the Mitoquinone (MitoQ) page · PubMed 34419082 (opens PubMed)
Grade CAerobic endurance performance and exercise-induced oxidative damage · No difference
Meta-analysis, 8 studies · n 188 · 2024 · Adults in placebo-controlled exercise studies, including people with peripheral artery disease
Varied across studies (acute and chronic dosing) · Varied across studies
No improvement in endurance performance (SMD −0.50, 95% CI −1.39 to 0.40), although exercise-induced oxidative damage was lower (SMD −1.33). A sensitivity analysis suggested better exercise tolerance in peripheral artery disease.
Row on the Mitoquinone (MitoQ) page · PubMed 38981985 (opens PubMed)